Psilocybin
Swedish Nonprofit Announces $3 Million in Funding for Psychedelic Studies
The initiative has already helped fund two research programs in Sweden.
The post Swedish Nonprofit Announces $3 Million in Funding for Psychedelic Studies…
In another nod to the growing global interest in the potential of psychedelic-based medicines, Swedish nonprofit the Norssken Foundation announced this week that it’s launched a new initiative to deliver €3 million in capital to various psychedelic medical studies in the Scandinavian country.
The initiative, called Norrsken Mind: Psychedelic Science Initiative, has already awarded €587,000 in grant money to studies at Karolinska Institutet for a psilocybin therapy study and another at Umeå University for an MDMA therapy study, according to Tech.eu and the Norrsken website.
Both programs are aimed at treating mental health issues, with the psilocybin study targeting major depressive disorder and the MDMA study focused on depression in young adults.
“There is an ever-growing awareness of the importance of investing in mental health,” Norrsken Mind Managing Director Emma Christersson told Tech.eu.
“While there are several important mental health treatments today, they are in many cases insufficient, and we need to explore new ways forward,” Christersson said. “Research on psychedelic-assisted treatments is one of the most promising lines of research in the field of psychiatry right now. There are plenty of interested researchers in Sweden and across Europe. With the right funding and conditions in place, we can help them investigate more effective treatment options through rigorous research.”
The nonprofit also said the €3 million – about $3.2 million in U.S. dollars – is only the beginning, and it plans to raise and deploy even more capital into psychedelics research outside of Sweden in the near future.
The post Swedish Nonprofit Announces $3 Million in Funding for Psychedelic Studies appeared first on Green Market Report.
psilocybin mdma psychiatry psychedelic therapy major depressive disorder depressive disorder depression psychedelics investing funding capital psychedelic science research
Compass Pathways keeps plugging away with its psilocybin study trials
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
MindMed Reports First Quarter 2024 Financial Results and Business Updates
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psychedelics7 days agoMindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics1 week agoFreedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Law & Regulation1 week ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics7 days agoReunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics7 days agoCompass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Ketamine1 week agoDEA poised to move cannabis to Schedule III
-
Psychedelics1 week agoAre ‘Ketamine Bros’ Ruining It for Everyone Else?
-
Psychedelics1 week agoBehold! A New Mushroom Emoji Has Arrived!